



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Frontiers Production Office
✉ production.office@frontiersin.org

SPECIALTY SECTION

This article was submitted to Drug, Venom & Anaphylaxis, a section of the journal Frontiers in Allergy

RECEIVED 10 March 2023

ACCEPTED 10 March 2023

PUBLISHED 03 April 2023

CITATION

Frontiers Production Office (2023) Erratum: Intradermal testing with COVID-19 mRNA vaccines predicts tolerance. *Front. Allergy* 4:1183702. doi: 10.3389/falgy.2023.1183702

COPYRIGHT

© 2023 Frontiers Production Office. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Erratum: Intradermal testing with COVID-19 mRNA vaccines predicts tolerance

Frontiers Production Office*

Frontiers Media SA, Lausanne, Switzerland

KEYWORDS

SARS-CoV-2, allergy, vaccine, polyethylene glycol, PEG, COVID-19, anaphylaxis, basophil activation test

An Erratum on Intradermal testing with COVID-19 mRNA vaccines predicts tolerance

By Stehlin F, Mahdi-Aljedani R, Canton L, Monzambani-Banderet V, Miauton A, Girard C, Kammermann K, Meylan S, Ribic C, Harr T, Yerly D and Muller YD. (2022) *Front. Allergy* 3:818049. doi: 10.3389/falgy.2022.818049

An omission to the **Funding** section of the original article was made in error. The following sentence has been added: “Open access funding provided by University of Lausanne”.

The original version of this article has been updated.